# Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma

> **NCT07692152** · PHASE3 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 350 (estimated)

## Conditions studied

- Anal Squamous Cell Carcinoma, Limited-stage

## Interventions

- **RADIATION:** Intensity-Modulated Radiotherapy (IMRT)
- **DRUG:** Capecitabine
- **BIOLOGICAL:** Sintilimab
- **DRUG:** Mitomycin (MMC)

## Key facts

- **NCT ID:** NCT07692152
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-17
- **Primary completion:** 2029-03
- **Final completion:** 2029-03
- **Target enrollment:** 350 (ESTIMATED)
- **Last updated:** 2026-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07692152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07692152, "Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07692152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*